Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 randomized double-blind study of lusvertikimab in moderate to severe ulcerative colitis
2020-001398-59Phase 2Completed
- Sponsor
- OSE Immunotherapeutics
- Start
- Jul 2020
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in autoimmune colitis comparing Lusvertikimab with Placebo (2 arms). Primary endpoint: Mean change from baseline in modified Mayo Score at Week 10. Started Jul 2020; status: completed.
02
Drugs
lusvertikimab
03
Conditions
autoimmune colitis
Beyond the preview
Go deeper on 2020-001398-59.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-001398-59.